The headline EPS beat was substantial, but revenue missed. Published Q2 expectations were roughly $215–219 million of revenue and $4.95–5.05 of EPS; Nutex delivered $210.8 million of revenue and $9.38 diluted EPS.
| Metric | Q2 2026 | Q2 2025 | Published expectation |
|---|---|---|---|
| Total revenue | $210.8M (Income Statement) | $244.0M (Income Statement) | ~$215–219M |
| Diluted EPS | $9.38 (Income Statement) | $(2.95) (Income Statement) | ~$4.95–5.05 |
| Adjusted EBITDA | $90.0M (Adjusted EBITDA reconciliation) | $71.6M (Adjusted EBITDA reconciliation) | — |
| Operating cash flow, six months | $109.7M (Cash Flow statement) | $78.2M (Cash Flow statement) | — |
The earnings beat is real but unusually dependent on cost reversals and accounting items. Contract-services expense fell to $1.1 million from $61.1 million, including a $52.3 million benefit from a retroactive HaloMD agreement amendment and lower CMS arbitration fees (Income Statement; Financial Highlights). Stock-based compensation also shifted from a $78.7 million expense to a $2.9 million expense in the quarter (Income Statement). Those changes lifted operating income to $121.7 million from $33.7 million, so the reported margin improvement is much larger than the underlying revenue trend alone would suggest.
The more durable improvement is lower future arbitration costs, but it is not yet a clean growth result. Management expects the contractual and regulatory changes to reduce normalized historical contract-services expense by roughly 25–30% prospectively (Financial Highlights). That supports better recurring profitability, but hospital revenue declined 14% year over year in the quarter, while same-hospital revenue fell 12.1% (Financial Highlights). Population-health revenue grew to $8.9 million from $7.7 million, but not enough to offset the hospital decline (Income Statement).
Cash generation and the balance sheet improved, though working-capital exposure remains material. Six-month operating cash flow rose to $109.7 million from $78.2 million, and cash plus restricted cash reached $207.1 million (Cash Flow statement). Nutex also spent $50.7 million on stock repurchases and paid $28.6 million in member distributions (Cash Flow statement). However, accounts receivable increased to $351.7 million from $319.4 million at year-end, and long-term debt edged up to $31.1 million from $29.2 million (Balance Sheet), leaving collections and arbitration recoveries important to the cash-flow picture.
Net read: mixed versus expectations. The large EPS beat and lower prospective arbitration-cost structure are meaningful positives, but the revenue miss, double-digit same-hospital contraction, and heavy contribution from a retroactive $52.3 million cost adjustment make this less clean than the headline earnings number suggests.
Read the original 8-K on SEC EDGAR ↗